Fibrocell Science Inc (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
A number of other research firms have also recently weighed in on FCSC. ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. HC Wainwright reiterated a “buy” rating and set a $5.70 price target on shares of Fibrocell Science in a report on Friday, June 9th. Finally, Canaccord Genuity restated a “buy” rating and set a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Fibrocell Science currently has an average rating of “Hold” and an average target price of $4.74.
Shares of Fibrocell Science (FCSC) opened at 3.38 on Friday. The company has a 50 day moving average price of $2.92 and a 200 day moving average price of $2.60. Fibrocell Science has a 12-month low of $0.52 and a 12-month high of $4.64. The company’s market capitalization is $49.74 million.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. Equities analysts anticipate that Fibrocell Science will post ($2.17) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/09/17/fibrocell-science-inc-fcsc-stock-rating-upgraded-by-zacks-investment-research.html.
A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC boosted its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,259 shares of the company’s stock after acquiring an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned 0.33% of Fibrocell Science worth $194,000 at the end of the most recent quarter. 54.70% of the stock is currently owned by institutional investors.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.